- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.09. | GRI Bio Stock Rallies 37% On Positive Phase 2a Data For IPF Treatment | 6 | RTTNews | ||
| 11.09. | GRI Bio, Inc.: GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis ("IPF") | 1 | GlobeNewswire (USA) | ||
| 14.08. | GRI Bio, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| GRI BIO Aktie jetzt für 0€ handeln | |||||
| 13.08. | GRI Bio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 13.08. | GRI Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 31.07. | GRI Bio, Inc.: GRI Bio CEO, Marc Hertz, Participates in Virtual Investor "What This Means" Segment | 1 | GlobeNewswire (USA) | ||
| 31.07. | GRI Bio: Positive Biomarker-Daten in Studie zur Behandlung von Lungenfibrose | 4 | Investing.com Deutsch | ||
| 31.07. | GRI Bio reports positive interim biomarker results in IPF treatment study | 1 | Investing.com | ||
| 31.07. | GRI Bio, Inc.: GRI Bio Reports 6-Week Interim Biomarker Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis ("IPF") | 160 | GlobeNewswire (Europe) | Biomarkers at 6-week interim analysis show a positive impact on fibrogenesis, fibrolysis and potentially the initiation of a repair response The Independent Data Monitoring Committee (IDMC) has recommended... ► Artikel lesen | |
| 31.07. | GRI Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 02.07. | GRI Bio-Aktie behält Kaufempfehlung von H.C. Wainwright nach Abschluss der Phase-2a-Studie | 1 | Investing.com Deutsch | ||
| 02.07. | GRI Bio stock holds Buy rating at H.C. Wainwright as Phase 2a trial completes enrollment | 2 | Investing.com | ||
| 01.07. | GRI Bio, Inc.: GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis ("IPF") | 358 | GlobeNewswire (Europe) | Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, limited patient compliance and no impact on survival 2- and 6-week interim safety... ► Artikel lesen | |
| 26.06. | GRI Bio meldet positive Sicherheitsdaten für IPF-Behandlungskandidat | 2 | Investing.com Deutsch | ||
| 26.06. | GRI Bio, Inc.: GRI Bio's GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis ("IPF") | 239 | GlobeNewswire (Europe) | The Independent Data Monitoring Committee ("IDMC") has recommended to continue the study as planned as there are no safety concerns demonstrated in the data reviewed Interim results to date demonstrate... ► Artikel lesen | |
| 26.06. | GRI Bio, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 11.06. | H.C. Wainwright REITERATES Buy rating on GRI Bio stock | 3 | Investing.com | ||
| 23.05. | GRI Bio erweitert Kapazität für At-the-Market-Angebot | 2 | Investing.com Deutsch | ||
| 23.05. | GRI Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.05. | GRI Bio reports progress in pulmonary fibrosis treatment | 1 | Investing.com |
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,60 | +0,44 % | Turbulenzen im Biotechsektor - BioNTech, CureVac, Moderna, Vidac Pharma | Nach der stetigen Eskalation im Handelskrieg der beiden führenden Wirtschaftsnationen der Welt, USA und China, meldete der US-Finanzminister Scott Bessent, dass er zuversichtlich bezüglich des Treffens... ► Artikel lesen | |
| EVOTEC | 7,054 | -0,59 % | EQS-News: Evotec SE: Evotec gibt Fortschritt in präklinischer Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotec gibt Fortschritt in präklinischer Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt
27.10.2025 / 07:30 CET/CEST
Für... ► Artikel lesen | |
| CUREVAC | 4,572 | -1,08 % | BionTech Aktie startet Übernahme von CureVac - Jetzt Aktien kaufen? | ||
| AMGEN | 259,70 | +0,78 % | Amgen Announces 2025 Fourth Quarter Dividend | THOUSAND OAKS, Calif., Oct. 31, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the... ► Artikel lesen | |
| VIKING THERAPEUTICS | 33,520 | +1,53 % | Viking Therapeutics stock rises ahead of obesity drug presentations at medical conferences | ||
| DEFENCE THERAPEUTICS | 0,460 | -4,76 % | Defence Therapeutics Inc.: Defence to Present New Scientific Data on Its ADC-Enhancing Accum Technology at the World ADC Conference in San Diego, USA, November 4-5, 2025 | Montreal, Quebec--(Newsfile Corp. - October 23, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,439 | -2,23 % | NurExone Biologic: Rallye abgewürgt - jetzt die zweite Chance! | ||
| ABIVAX | 90,20 | +0,67 % | EQS-News: ABIVAX: Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies | EQS-News: ABIVAX
/ Key word(s): Conference/Study results
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without... ► Artikel lesen | |
| IBIO | 1,340 | -2,90 % | iBio, Inc. - 8-K, Current Report | ||
| ARROWHEAD PHARMACEUTICALS | 37,020 | +0,82 % | Arrowhead Pharmaceuticals vor FDA-Entscheidung: Attraktive Kaufchance? | Arrowhead Pharmaceuticals steht kurz vor entscheidenden Weichenstellungen, die den langfristigen Erfolg des Unternehmens maßgeblich beeinflussen könnten. Rückenwind gibt's aktuell durch einen starken... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 4,054 | +0,15 % | Exosomen statt Viren: Warum NurExone, Regenxbio und Voyager den Markt für Nerventherapien verändern könnten | ||
| OPGEN | 2,600 | 0,00 % | OPGEN INC - 10-Q, Quarterly Report | ||
| MEREO BIOPHARMA | 1,630 | -0,91 % | Mereo BioPharma Group plc: Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights | Data from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta expected around year-end 2025 Cash of $56.1 million as of June 30, 2025, expected to support operations into 2027... ► Artikel lesen | |
| APELLIS PHARMACEUTICALS | 18,802 | +0,87 % | Apellis Pharmaceuticals, Inc.: Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results | Generated $459 million in 3Q 2025 revenues, including $178 million in U.S. net product salesReceived 152 new patient start forms for EMPAVELI® (pegcetacoplan) in the first two months since launch... ► Artikel lesen | |
| CYBIN | 6,400 | +1,59 % | Cybin Inc (2): Cybin closes $175-million (U.S.) offering |
GRI BIO INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +8,12 % bei einem Aktienkurs von 1,730 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GRI BIO INC finden Sie auf Wallstreet Online.